MYOZYME Drug Profile

Summary for Tradename: MYOZYME

High Confidence Patents:	4
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for MYOZYME

Recent Clinical Trials for MYOZYME

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Valerion Therapeutics, LLC	Phase 1/Phase 2
Sanofi	Phase 3
Amicus Therapeutics	Phase 2

See all MYOZYME clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for MYOZYME Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for MYOZYME Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141		2016-07-29	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141		2021-07-10	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141		2023-06-30	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141		2028-01-30	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for MYOZYME Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141		2036-12-20	Patent claims search
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141		2038-12-19	Patent claims search
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141		2034-05-02	Patent claims search
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141		2038-07-09	Patent claims search
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141		2038-09-17	Patent claims search
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141		2035-12-07	Patent claims search

International Patents for MYOZYME

Country	Patent Number	Estimated Expiration
Spain	2312222
European Patent Office	0845939
Spain	2200071
Australia	6789096
Denmark	2020438
Japan	2012224643

Supplementary Protection Certificates for MYOZYME

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2018C/038	Belgium		PRODUCT NAME: ALPHA ALGLUCOSIDASE; AUTHORISATION NUMBER AND DATE: EU/1/06/333/001-003 20060331
300382	Netherlands		PRODUCT NAME: ALGLUCOSIDASE ALFA; REGISTRATION NO/DATE: EU/1/06/333/001-003 20060329
544	Finland
300954	Netherlands		PRODUCT NAME: ALGLUCOSIDASE ALFA; REGISTRATION NO/DATE: EU/1/06/333/001-003 20060331
CA 2018 00030	Denmark		PRODUCT NAME: ALGLUCOSIDASE ALFA; REG. NO/DATE: EU/1/06/333 20060331
8/2009	Austria		PRODUCT NAME: ALGLUCOSIDASE ALFA; REGISTRATION NO/DATE: EU/1/06/333/001-003 20060329

MYOZYME (alglucosidase alfa): Market dynamics and financial trajectory

Last updated: April 23, 2026

How did MYOZYME’s market position shift over time?

MYOZYME (alglucosidase alfa) is an enzyme replacement therapy (ERT) for late-onset and infantile-onset Pompe disease. Its commercial trajectory has been shaped by (1) disease prevalence growth, (2) hospital and payer adoption patterns typical for ERTs, (3) competition from next-generation ERTs and biosimilars, and (4) pricing pressure as payers seek value-linked terms.

Core dynamics

• Indication breadth widened by clinical label evolution through regulatory approvals across geographies, which expanded addressable patient counts over time.
• Hospital acquisition cycles for ERTs tend to be multi-step (formulary inclusion, prior authorization, budget approval), so adoption after label updates usually follows a delayed curve rather than an immediate step-function.
• Competitive pressure intensified as alternative ERTs and biosimilar entrants gained traction in national formularies, and as payers negotiated tighter pricing.
• “Treatable population” changed as diagnostic capability increased, pulling more patients into care.

What financial trajectory did MYOZYME show in reported company disclosures?

MYOZYME’s financial performance is reported within Sanofi’s Biopharma segment reporting and, for some periods, in legacy enzyme replacement therapy lines. The drug’s lifecycle includes the post-peak period where revenue growth generally slows, then declines as competition and payer pressure increase.

Key points used by market participants

• Early revenue scaling reflected broad adoption of ERT in Pompe.
• Mid-to-late lifecycle performance reflected new entrants and pricing negotiation intensity, which typically drives net price and patient share changes even when treated patients rise.

Revenue signal patterns observed in lifecycle

Because MYOZYME’s revenue is reported within Sanofi segment disclosures and in historical investor materials, the practical market read has been:

• Peak period: strong uptake after earlier approvals and scaling of treatment centers.
• Mature period: slower growth and then margin compression from price pressure and substitution.
• Later period: net sales decline or stagnation depending on geography and payer contracting.

Where does competitive pressure come from?

Competition for Pompe ERT includes:

• Next-generation ERTs that aim for improved efficacy, manufacturing, or dosing convenience.
• Biosimilar entrants (where regulatory pathways allow) that can reduce unit costs.
• Payer-driven switching through tendering or preferred-product policies.

Market participant impact

• Competitive switching in ERT categories often occurs at the level of payer policy and center formulary, not just at the patient level.
• Even without immediate substitution, pricing negotiations usually start once a payer believes an alternative is available.

How do pricing and contracting dynamics affect MYOZYME’s net revenue?

For high-cost biologics like MYOZYME, gross-to-net dynamics dominate financial outcomes:

• Rebates and discounts tied to payer volume, performance clauses, or budget caps.
• Patient access pathways where payer authorization and co-pay support shift net sales timing.
• Global reference pricing and negotiated country-level reimbursement levels constrain list price translation.

Typical ERT payer stance

• Payers focus on total cost of treatment rather than only acquisition cost.
• Contracting tends to shift from list price to negotiated net price as competitive options increase.

What supply-chain and manufacturing factors can affect market access?

Operational continuity matters because ERT treatment must be uninterrupted.

• Manufacturing capacity and batch release performance influence treatment availability and can create access delays.
• Scale-up events and technology transfer can reduce supply risk, but can also create transition periods.

These factors affect:

• Hospital confidence (fewer stock-out concerns support sustained ordering)
• Payer willingness to contract (continuity reduces enforcement risk for payers and providers)

How do regulatory and reimbursement decisions shape uptake?

MYOZYME adoption follows reimbursement availability.

• Once a country places Pompe on funded pathways, treated prevalence tends to rise with diagnostic expansion.
• Prior authorization requirements shape the speed of conversion from diagnosed patients to treated patients.

Regulatory decisions also impact:

• Label expansions that change eligibility criteria
• Use restrictions that can limit access for specific subpopulations

What is MYOZYME’s competitive context versus other Pompe therapies?

The market’s financial outcomes for MYOZYME are best understood as a share game across geographies:

• When alternative products gain preferred status, patient share shifts.
• Even without full substitution, net price declines can occur as contracts are renegotiated.

The competitive set for Pompe includes:

• alglucosidase alfa (MYOZYME)
• other ERTs in Pompe disease
• potential biosimilar competition where approved and tendered

How does patient population growth translate into sales?

Pompe’s treated population growth has two components:

1. Diagnosed prevalence increase driven by improved testing and screening.
2. Treatment initiation rate influenced by reimbursement, clinical guidance, and center experience.

For ERTs, treated prevalence does not always rise in lockstep with diagnosis:

• Some patients may not meet reimbursement or clinical criteria initially.
• Therapy persistence is high in ERT categories, so share shifts rather than frequent discontinuations drive lifecycle change.

What investment and business implications follow from MYOZYME’s market dynamics?

For R&D prioritization

• Competitive entry triggers payer-level switching. Product differentiation must address not only efficacy but also payers’ contracting levers (monitoring burden, dosing convenience, and claims support).
• When disease prevalence growth exists, incumbents still face net price erosion if alternative options appear.

For valuation and pipeline timing

• For incumbents or near-terms entrants, cashflow sensitivity is driven more by net price and share than by treated prevalence alone.
• Entering with superior dosing convenience or with evidence that supports fewer payer denials can shift realized sales earlier in the lifecycle.

For commercial strategy

• Contracting needs to anticipate reference pricing and budget caps.
• Hospital ordering behavior can outlast payer policy changes, but only if supply continuity is stable and authorization pathways remain fast.

---

Key Takeaways

• MYOZYME’s market dynamics have followed a standard ERT lifecycle: early adoption and expansion, then slower growth as pricing pressure and competitive products increase payer leverage.
• Financial trajectory is driven mainly by net price and patient share, not just diagnosed prevalence.
• Competition in Pompe tends to shift through payer formularies and center contracting, leading to delayed but durable share changes.
• Contracting and reimbursement mechanics determine whether treatment growth converts into realized net sales.

---

FAQs

1. What drives MYOZYME sales beyond patient growth?
   Net pricing through rebates/discounts, payer formulary status, and center-level contracting that determines whether diagnosed patients start therapy.

2. How does competition typically affect an ERT incumbent like MYOZYME?
   It reduces patient share via preferred product policies and forces renegotiation of net price through contracting and tendering.

3. Why do ERT revenues often show delayed changes after regulatory events?
   Uptake depends on formulary inclusion, prior authorization criteria, and budget approvals, which follow multi-step procurement timelines.

4. Does improved diagnosis always translate directly into MYOZYME revenue growth?
   Not directly. A portion of diagnosed patients may face reimbursement or eligibility constraints, and initiation timing depends on contracting and access pathways.

5. What operational factors can influence commercialization for MYOZYME?
   Manufacturing reliability and uninterrupted supply are critical for chronic ERT, influencing hospital ordering stability and payer confidence in continued coverage.

---

References

[1] Sanofi. FY 2023 and FY 2024 financial reports and investor presentations (Biopharma segment materials). Sanofi.
[2] U.S. Food and Drug Administration (FDA). Product label information for MYOZYME (alglucosidase alfa). FDA.
[3] European Medicines Agency (EMA). Assessment history and product information for MYOZYME (alglucosidase alfa). EMA.
[4] World Health Organization. ATC classification and background information for enzyme replacement therapies used in rare diseases (general reference context). WHO.